Stephen A. Hill is Director at Cellectar Biosciences, Inc. (CLRB). They have made 7 open-market trades across 4 companies since 2013, most recently 2020-12-16.
CIK 0001237404
6 open-market purchases totalling $178K since 2013, against 1 sale. Across 5 scored buys the stock is up 4.8% at ninety days, and 2.6 points ahead of the S&P over the same stretch.
5 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 20% | 60% | 60% |
| Avg Move | -6.5% | +22.4% | +4.8% |
| Alpha | -3.7% | +24.1% | +2.6% |
| Scored | 5 | 5 | 5 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| CLRB | BUY | 2020-06-04 | 2020-06-08 | $1.08 | $19K | -10.4% | +14.2% | -20.9% |
| CLRB | SELL | 2018-11-29 | 2018-11-30 | $2.21 | $2K | -3.5% | -32.0% | -11.0% |
| LPCN | SELL · 10b5-1 | 2017-12-29 | 2018-01-02 | $3.47 | $4K | -50.7% | -58.8% | -56.5% |
| CLRB | BUY | 2016-04-20 | 2016-04-21 | $2.12 | $20K | -9.7% | +108.7% | +31.8% |
| CBIO | BUY | 2015-12-17 | 2015-12-18 | $2.03 | $10K | -22.0% | -20.6% | +3.2% |
| LPCN | BUY | 2014-11-13 | 2014-11-13 | $4.95 | $20K | -17.9% | +0.0% | +0.0% |
| CLRB | BUY | 2014-08-20 | 2014-08-22 | $3.75 | $20K | +27.3% | +9.9% | +9.9% |
| TRGT | BUY | 2013-03-08 | 2013-03-11 | $4.43 | $89K | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.